{
    "clinical_study": {
        "@rank": "3020", 
        "arm_group": [
            {
                "arm_group_label": "ONO-8539", 
                "arm_group_type": "Experimental", 
                "description": "ONO-8539"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "A random controlled study to investigate the effect of a new drug, ONO-8539, on oesophageal\n      pain hypersensitivity in patients with gastric reflux disease"
        }, 
        "brief_title": "A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease", 
        "condition": "GERD", 
        "condition_browse": {
            "mesh_term": [
                "Hypersensitivity", 
                "Gastroesophageal Reflux"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Randomised, Double-blind, Placebo-controlled, Two-period Crossover Study to\n      Investigate the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With\n      Non-erosive Reflux Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects aged 18-70 years inclusive with confirmed GERD and normal\n             oesophageal mucosa will be enrolled in this study. Subjects demonstrate moderate\n             intensity heartburn while being on a stable dose of proton pump inhibitor and\n             demonstrate oesophageal hypersensitivity following distal oesophageal acid perfusion.\n\n        Exclusion Criteria:\n\n          -  Subjects will be excluded if they have a motility disorder, are not able to tolerate\n             study procedures or have had GI surgery or have a condition that would affect the\n             study results. Subjects with functional heartburn, acute GI symptoms, endoscopic or\n             manometric abnormality or a protocol-specified cardiovascular condition will not be\n             enrolled."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707901", 
            "org_study_id": "ONO-8539POE011"
        }, 
        "intervention": [
            {
                "arm_group_label": "ONO-8539", 
                "description": "Treatment", 
                "intervention_name": "ONO-8539", 
                "intervention_type": "Drug", 
                "other_name": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "B-3000"
                    }, 
                    "name": "Leuven Clinical site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "E1 2AJ"
                    }, 
                    "name": "London Clinical site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Two-period Crossover Study to Investigate the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease", 
        "overall_contact": {
            "last_name": "Ono Pharma UK Ltd", 
            "phone": "+44 (0)2074214920"
        }, 
        "overall_contact_backup": {
            "last_name": "Study Director"
        }, 
        "overall_official": {
            "affiliation": "Clinical Department, Ono Pharmaceutical Co. Ltd", 
            "last_name": "Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Belgium: Federal Agency for Medicinal Products and Health Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Daily, through a pain assessment score chart", 
            "measure": "To evaluate the effect of ONO-8539 on oesophageal pain hypersensitivity to acid perfusion", 
            "safety_issue": "No", 
            "time_frame": "28 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707901"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Daily, by observation", 
                "measure": "To evaluate the effect of ONO-8539 on subject-reported symptoms of GERD", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "Daily, through observation", 
                "measure": "To assess the tolerability of ONO-8539", 
                "safety_issue": "Yes", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "Daily, through observation and a pain score chart", 
                "measure": "To investigate the effect of ONO-8539 on oesophageal pain hypersensitivity to electrical stimulation", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "Daily, through Quality of life assessment questionnaires", 
                "measure": "To evaluate the effect of ONO-8539 on quality of life", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "AUC, Cmax, Tmax\nConcentrations of ONO-8539", 
                "measure": "To investigate the pharmacokinetics of ONO-8539", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "Daily observation and through Quality of life assessment questionnaires", 
                "measure": "To investigate the association among the changes in pharmacodynamics of ONO-8539", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "Correlation between pharmacokinetic results and study specific procedure results", 
                "measure": "To investigate the association between the changes in pharmacodynamic parameters of ONO-8539 and the plasma concentrations of ONO-8539", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "Daily record of frequency of use", 
                "measure": "To evaluate the use of antacid in each treatment group", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "To assess the safety of ONO-8539", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Psychological parameters", 
                "measure": "To investigate the association among the changes in psychological parameters of ONO-8539", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "source": "Ono Pharmaceutical Co. Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ono Pharmaceutical Co. Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}